에 대한 최신 뉴스 GFL Environmental (NYSE:GFL) 주식

GFL Environmental

GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. GFL's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.

News

Movers

COHR

COIN

CRWD

ESTC

GWRE

ILMN

NVDA

PLTR

RDDT

SAIA

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 가이드와이어 소프트웨어(NYSE:GWRE)의 주가는 회사가 예상보다 나은 3분기 재무 결과를 보고하고 예상보다 높은 2024회계연도 매출 지침을 발표한 후 14.08% 급등했다. 몇몇 분석가는 예측치를 상향 조정했다. 

Arm과 보잉은 지난주 최고의 성과를 보인 10개의 대형주 중 일부 (6월 1일-6월 7일)

GFL Environmental Inc. Subordinate voting shares, no par value

GFL Environmental Inc

GENFLAT HOLDINGS INC. by GenFlat Holdings, Inc.

GenFlat Holdings Inc

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

Cannabis

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Markets

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

Earnings

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

Luna Innovations Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNA#NASDAQ">LUNA</a>) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that it has received a written notice (the "Notice") on November 14, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the quarter ended September 30, 2024 (the "Q3 2024 Form 10-Q") and because the Company remains delinquent in filing its Form 10-Qs for the quarters ended March 31, 2024 (the "Q1 2024 Form 10-Q") and June 30, 2024 (the "Q2 2024 Form 10-Q") and its Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K", and collectively with the Q1 2024 10-Q, Q2 2024 10-Q and Q3 2024 10-Q, the "Delinquent Filings"), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). As previously announced, the Company received earlier notices of non-compliance with respect to the Rule on August 20, 2024, May 17, 2024 and April 2, 2024 because it had not yet filed its Q2 2024 Form 10-Q, Q1 2024 Form 10-Q and 2023 Form 10-K, respectively.
This Notice has no immediate effect on the listing of the Company's shares on Nasdaq. However, if the Company fails to timely regain compliance with the Rule, the Company's common stock will be subject to delisting from Nasdaq.
As previously disclosed on October 7, 2024, the Company intended to appeal a determination by the Nasdaq Listing Qualifications Department to delist the Company's securities due to the Company's Delinquent Filings. On October 8, 2024, the Company timely requested a hearing before the Nasdaq Hearings Panel (the "Panel") and requested that the automatic stay of suspension be extended through the completion of the hearings process and the expiration of any additional extension period granted by the Panel following the hearing. The hearing is scheduled for November 26, 2024 and the request for the automatic stay of suspension was granted.
The Company is working diligently to complete its Delinquent Filings and will provide an update once more information is available.

LUNA

Luna Innovations Receives Additional Notice From Nasdaq Regarding Late Filing Of Quarterly Report On Form 10-Q; Hearing Is Scheduled For November 26, 2024 And The Request For The Automatic Stay Of Suspension Was Granted

Barrington Research analyst Kevin Steinke maintains HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) with a Outperform and raises the price target from $17 to $18.

Barrington Research Maintains Outperform on HireQuest, Raises Price Target to $18

Barrington Research analyst Vincent Colicchio maintains Alithya Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALYA#TSX">ALYA</a>) with a Outperform and maintains C$3.5 price target.

TSX:ALYA

Barrington Research Maintains Outperform on Alithya Group, Maintains C$3.5 Price Target

Lifeway Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) ("Lifeway" or the "Company"), a leading U.S. supplier of kefir and fermented probiotic products to support the microbiome, confirmed that it has received a revised, unsolicited, non-binding proposal from Danone North America PBC ("Danone") to acquire all outstanding shares of common stock of Lifeway it does not already own for $27.00 per share in cash. According to the Schedule 13D amendment filed today with the U.S. Securities and Exchange Commission disclosing the revised proposal, Danone beneficially owns approximately 23.3% of Lifeway's outstanding common stock.
On November 5, 2024, Lifeway announced that its Board of Directors (the "Board") had rejected Danone's initial unsolicited, non-binding proposal to acquire all the shares of Lifeway that it does not already own for $25.00 per share because the Board determined that the initial proposal substantially undervalued Lifeway and was not in the best interests of the Company and its shareholders and other stakeholders.
Consistent with its fiduciary duties, Lifeway's board of directors, in consultation with its independent outside advisors, will carefully review and evaluate the revised proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders and other stakeholders.
The Company does not undertake any obligation to provide any updates with respect to this or any other proposal or transaction, except as required under applicable law.
Lifeway shareholders do not need to take any action at this time.
Evercore is serving as a financial advisor to Lifeway and Sidley Austin LLP is serving as legal counsel to Lifeway.

LWAY

Lifeway Foods Confirms Receipt Of Revised, Unsolicited, Non-Binding Proposal From Danone  To Acquire All Outstanding Shares Of Common Stock Of Lifeway It Does Not Already Own For $27.00 Per Share In Cash

Generation Income (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIPR#NASDAQ">GIPR</a>) reported quarterly losses of $(0.03) per share. This is unchanged from the same period last year. The company reported quarterly sales of $2.40 million which beat the analyst consensus estimate of $2.26 million by 6.21 percent. This is a 30.17 percent increase over sales of $1.84 million the same period last year.

Earnings Beats

GIPR

Generation Income Q3 FFO $(0.03), Same YoY, Sales $2.40M Beat $2.26M Estimate

Shareholders Approve Waiver Of 19.99% Limit To Enable Additional Stock Issuance

Stock Split

LUXH

LuxUrban Hotels Announces 1-For-70 Reverse Stock Split Effective Nov. 20 To Strengthen Nasdaq Compliance

Scotiabank analyst Konark Gupta maintained a Buy rating on GFL Environmental (GFL – Research Report) today and set a price target of $51.00. The co...

GFL Environmental (GFL) Gets a Buy from Scotiabank

Truist raised the firm's price target on GFL Environmental (GFL) to $54 from $46 and keeps a Buy rating on the shares after its Q3 results. The man...

GFL Environmental price target raised to $54 from $46 at Truist

Scotiabank raised the firm's price target on GFL Environmental (GFL) to $51 from $50 and keeps an Outperform rating on the shares. The company deli...

GFL Environmental price target raised to $51 from $50 at Scotiabank

National Bank raised the firm's price target on GFL Environmental (GFL) to C$70 from C$66 and keeps an Outperform rating on the shares. Published f...

GFL Environmental price target raised to C$70 from C$66 at National Bank

CIBC raised the firm's price target on GFL Environmental (GFL) to C$69 from C$64 and keeps an Outperformer rating on the shares. Published first on...

GFL Environmental price target raised to C$69 from C$64 at CIBC

GFL Environmental (TSE:GFL) has released an update. GFL Environmental Inc. reports a notable rise in revenue for the third quarter of 2024, reachin...

GFL Environmental Reports Strong Q3 Revenue Growth

GFL Environmental Inc. (GFL) Q3 2024 Earnings Call Transcript

In a report released yesterday, Brian Butler from Stifel Nicolaus maintained a Buy rating on GFL Environmental (GFL – Research Report), with a pric...

Stifel Nicolaus Sticks to Their Buy Rating for GFL Environmental (GFL)

George Soros' Soros Fund Management disclosed in an SEC filing its holdings as of September 30, 2024. Soros' new buys during the third quarter incl...

Soros boosts stake in AstraZeneca, exits Apple position

GFL Environmental: EBITDA Growth Should Accelerate From Here

AAPL

AXNX

AZNCF

BABA

BMRN

GOOG

GOOGL

LBRDA

LBRDK

SATS

Commodities

Press Releases

GFL Environmental Reports Second Quarter 2024 Results and Raises Full Year 2024 Guidance for the Second Time

GFL Environmental Inc. Announces Issuance of 16 million Subordinate Voting Shares on Conversion of Series A Preferred Shares

GFL Environmental Inc. Announces Proposed Offering of US$210 Million of Tax-Exempt Industrial Revenue Bonds

GFL Environmental Inc. Prices Offering of US$210 Million of Tax-Exempt Industrial Revenue Bonds at 4.375%

Dividends

GFL Environmental Inc. Announces Quarterly Dividend

GFL Environmental and OPAL Fuels Begin Commercial Operations of Their Second RNG Facility

GFL Environmental Inc. Sets Date for Q3 2024 Earnings Release

EARLY WARNING PRESS RELEASE PURSUANT TO NATIONAL INSTRUMENT 62-103 - TAKE OVER BIDS AND ISSUER BIDS

GFL Environmental Reports Third Quarter 2024 Results

OPAL

TSX:GFL

Raymond James

Truist Securities

Scotiabank

RBC Capital

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>가이드와이어 소프트웨어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>)의 주가는 회사가 예상보다 나은 3분기 재무 결과를 보고하고 예상보다 높은 2024회계연도 매출 지침을 발표한 후 14.08% 급등했다. 몇몇 분석가는 예측치를 <a href="https://www.benzinga.com//node/39183330" target="_blank" rel="noreferrer noopener">상향 조정했다</a>.</li>
<li>GFL 인바이런먼털(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>)의 주가는 회사가 2건의 인수 제안을 검토하기 위해 금융 자문가를 고용했다는 내용의 보도 이후 11.62% 상승했다.</li>
<li>크라우드스트라이크 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)의 주가는 회사가 강력한 지침을 발표한 후 9.36% 상승했다. 몇몇 분석가들은 예측을 <a href="https://www.benzinga.com//node/39182501" target="_blank" rel="noreferrer noopener">재조정</a>했다.</li>
<li>Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)의 주가가 지난 주 9.26% 상승했습니다. 이는 지난 주에 <a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">엔비디아</a>의 주가가 상승하며 사상 최고치에 가까운 수준에서 거래를 마쳤다는 소식에 이어 일어난 일다.</li>
<li>일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)의 주가가 9.16% 상승했습니다. 이사회는 2024년 6월 12일경에 시작될 것으로 예상되는 &#8216;발행 시점&#8217; 거래인 그레일(GRAIL)의 분사를 승인했다.</li>
<li>사이아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>)의 주식은 8.31% 상승했다. 이는 회사가 <a href="https://www.benzinga.com//node/39155966" target="_blank" rel="noreferrer noopener">4월 근무일당</a> LTL 배송량이 18% 증가했다고 보고한 이후 일어났다.</li>
<li>엘라스틱 N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>)의 주가가 7.65% 상승했습니다.</li>
<li>코히런트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>)의 주가는 6월 3일부터 이사회가 짐 앤더슨(Jim Anderson)을 <a href="https://www.benzinga.com/pressreleases/24/06/g39134653/coherent-appoints-jim-anderson-as-chief-executive-officer" target="_blank" rel="noopener">새로운 CEO</a>로 임명하면서 지난주 7.12% 상승했다.</li>
<li>팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)의 주가가 7.02% 상승했다. 이는 회사의 <a href="https://www.benzinga.com//node/39223353" target="_blank" rel="noreferrer noopener">AIPCon 이벤트</a>가 주식 가격에 영향을 미쳤기 때문다.</li>
<li>보잉(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): 2018년과 2019년에 346명의 사망자를 낸 치명적인 충돌 사고에 대해 <a href="https://www.benzinga.com//node/39142764" target="_blank" rel="noopener">경영진이 형사 고발을 당할 가능성이 낮다</a>는 로이터 통신의 보도 이후 지난주 주가는 6.82% 상승했다.</li>
</ol>
위키미디어 커먼즈를 통한 사진
기사 더 읽어보기: <a href="https://www.benzinga.com/news/24/06/39243316/gamestop-and-nio-were-among-the-11-biggest-large-cap-losers-last-week-june-1-june-7-are-these-in-you">게임스탑과 니오는 지난주 최악의 성과를 보인 11개의 대형주 중 일부 (6월 1일-6월 7일)</a>

Comments

GFL Environmental

뉴스

에 대한 최신 뉴스 GFL Environmental (NYSE:GFL) 주식

일요일, 6월 09, 2024

뉴스

파트너 / 기고자

벤징가 글로벌